出海!泽安生物&礼来达成合作,助力自免管线研发

药时代
30 Jul

全文共1909字,共0图预计阅读时间:5分钟2025年7月29日,LTZ Therapeutics(泽安生物)宣布与礼来达成合作,将针对选定靶点开发新型髓系细胞衔接器(MCE)药物,用于治疗自身免疫性疾病。根据协议条款,泽安生物将获得两位数的百万美元预付款和对公司的股权投资。此外,还将有资格获得临床前、临床、监管和商业里程碑付款,以及任何由此产生的商业化产品的净销售额的分级特许权使用费。泽安生物是...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10